Cargando…

Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect

BACKGROUND: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV. Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the growth of CD26+ cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Kohji, Hayashi, Mutsumi, Du, Wenlin, Ohnuma, Kei, Sakamoto, Michiie, Morimoto, Chikao, Yamada, Taketo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709605/ https://www.ncbi.nlm.nih.gov/pubmed/19555512 http://dx.doi.org/10.1186/1475-2867-9-17

Ejemplares similares

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
por: Hayashi, Mutsumi, et al.
Publicado: (2016)

Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription
por: Yamada, Kohji, et al.
Publicado: (2013)

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018)

Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis
por: Hayashi, Mutsumi, et al.
Publicado: (2019)

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue
por: Hatano, Ryo, et al.
Publicado: (2014)

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014)

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
por: Angevin, Eric, et al.
Publicado: (2017)

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
por: Kaneko, Yutaro, et al.
Publicado: (2021)

Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens
por: Hatano, Ryo, et al.
Publicado: (2019)

CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells
por: Okamoto, Toshihiro, et al.
Publicado: (2014)

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021)

CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected Female sex workers
por: Songok, Elijah M, et al.
Publicado: (2010)

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
por: Kobayashi, Eiji, et al.
Publicado: (2023)

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
por: Nakagawa, Kazuhiko, et al.
Publicado: (2021)

Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells
por: Beckenkamp, Aline, et al.
Publicado: (2015)

Apigenin upregulation of CD26/DPPIV on colon epithelial cells requires inhibition of casein kinase 2
por: Lefort, Émilie C., et al.
Publicado: (2020)

T-cell activation via CD26 and caveolin-1 in rheumatoid synovium
por: Ohnuma, Kei, et al.
Publicado: (2006)

P1369: HDAC INHIBITION INVOLVES CD26 EXPRESSION ON MULTIPLE MYELOMA CELLS VIA THE C-MYC/SP1-MEDIATED PROMOTER ACTIVATION AND OVERCOMES THERAPEUTIC RESISTANCE BY HUMANIZED ANTIBODY
por: Nishida, Hiroko, et al.
Publicado: (2023)

Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8(+)T Effector Memory Subset
por: Alonso, Núria, et al.
Publicado: (2015)

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines
por: Abe, Masako, et al.
Publicado: (2011)

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
por: Doonan, Bently P., et al.
Publicado: (2017)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
por: Koyanagi, Yu, et al.
Publicado: (2023)

Cd26/Dipeptidyl Peptidase IV in Context: The Different Roles of a Multifunctional Ectoenzyme in Malignant Transformation
por: Iwata, Satoshi, et al.
Publicado: (1999)

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning
por: Schwaiger, Elisabeth, et al.
Publicado: (2012)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses
por: Chang, Jer-Hwa, et al.
Publicado: (2018)

CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion
por: Havre, Pamela A, et al.
Publicado: (2013)

CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context
por: De Chiara, Loretta, et al.
Publicado: (2020)

CD26 expression on T cell lines increases SDF-1-α-mediated invasion
por: Havre, P A, et al.
Publicado: (2009)

CD26 and Cancer
por: Cordero, Oscar J.
Publicado: (2022)

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells
por: Itoh, Takumi, et al.
Publicado: (2021)

CD26 expression is attenuated by TGF‐β and SDF‐1 autocrine signaling on stromal myofibroblasts in human breast cancers
por: Mezawa, Yoshihiro, et al.
Publicado: (2019)

The influence of CD26(+) and CD26(−) fibroblasts on the regeneration of human dermo-epidermal skin substitutes
por: Michalak-Micka, Katarzyna, et al.
Publicado: (2022)

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma
por: AMATYA, VISHWA JEET, et al.
Publicado: (2012)

MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1
por: Wei, Zhenxing, et al.
Publicado: (2020)

CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis
por: Cordero, Oscar J., et al.
Publicado: (2015)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G(2)/M arrest induced by topoisomerase II inhibitors
por: Aytac, U, et al.
Publicado: (2003)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlqnrjhqglip6g5b9844k72p2k